Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/35926
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCONSTANTINOV, Ericka Oliveira
dc.contributor.authorBRIGIDO, Luis Fernando de Macedo
dc.contributor.authorFONSECA, Luiz Augusto M.
dc.contributor.authorCASSEB, Jorge
dc.contributor.authorVEIGA, Ana Paula R.
dc.contributor.authorMAGRI, Marcello M. C.
dc.contributor.authorMONTEIRO, Mariana A.
dc.contributor.authorROCHA, Rosana C.
dc.contributor.authorGASCON, Maria R. P.
dc.contributor.authorFERREIRA, Mauricio D.
dc.contributor.authorPOLIS, Thales J. B.
dc.contributor.authorNASCIMENTO, Najara A. de Lima
dc.contributor.authorLIMONGELLI, Isadora Id
dc.contributor.authorOLIVEIRA, Caro S.
dc.contributor.authorFONSECA, Luiz A. M.
dc.contributor.authorDUARTE, Alberto J. S.
dc.date.accessioned2020-06-01T14:51:23Z
dc.date.available2020-06-01T14:51:23Z
dc.date.issued2020
dc.identifier.citationAIDS RESEARCH AND HUMAN RETROVIRUSES, v.36, n.3, p.200-204, 2020
dc.identifier.issn0889-2229
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/35926
dc.description.abstractDrug resistance mutations (DRMs) can affect the success of the therapy and compromise new prevention strategies. Increasing rates of resistance to antiretroviral (ARV) drugs have been reported in some areas. This study evaluated the DRMs prevalence among patients at Hospital das Clinicas (Sao Paulo). Among treatment-naive patients, the prevalence of transmitted DRMs (Stanford Calibrated Population Resistance) was 8.4% (21/249), with 69% (75/109) of acquired resistance among treatment-experienced patients. Rates of transmitted DRM showed an increase (6.6% in 2002-2009 vs. 15.1% in 2010-2015, p = .05), from the first to the second decade, mainly due to mutations to the NNRTI (non-nucleoside reverse transcriptase inhibitor) class. Among treatment-experienced cases, a nonsignificant decrease overall, significant for the protease inhibitors (PIs) class, was documented. Subtype B predominated in both groups (78%), followed by subtype F, BF recombinants, and subtype C. Our results add to the growing evidence of an increase in transmitted DRM, document extensive DRM among experienced patients, and a decrease in resistance to PIs class that may reflect the increased use of boosted PIs and newer ARV classes in more recent years.eng
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)CAPES [001]
dc.language.isoeng
dc.publisherMARY ANN LIEBERT, INCeng
dc.relation.ispartofAIDS Research and Human Retroviruses
dc.rightsrestrictedAccesseng
dc.subjectHIV-1eng
dc.subjectdrug resistance mutationeng
dc.subjectantiretroviral therapyeng
dc.subjectBrazileng
dc.subjectresistance testeng
dc.subject.otherreverse-transcriptaseeng
dc.subject.otheremergent resistanceeng
dc.subject.othernaive patientseng
dc.subject.otherinfectioneng
dc.subject.othertherapyeng
dc.subject.otherpredictorseng
dc.subject.otherhiv/aidseng
dc.subject.otherregimenseng
dc.subject.othertrendseng
dc.subject.otherstateeng
dc.titlePrevalence of Antiretroviral Drug Resistance Mutations in HIV Seropositive Patients from an Outpatient Clinic of a Large University Hospital from Sao Paulo, Brazileng
dc.typearticleeng
dc.rights.holderCopyright MARY ANN LIEBERT, INCeng
dc.contributor.groupauthorADEE 3002 Outpatient Clinical Wor
dc.identifier.doi10.1089/aid.2019.0151
dc.identifier.pmid31842584
dc.subject.wosImmunologyeng
dc.subject.wosInfectious Diseaseseng
dc.subject.wosVirologyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalBRIGIDO, Luis Fernando de Macedo:Adolfo Lutz Inst, Dept Virol, Div Blood & Sexual Dis, Retrovirus Lab, Sao Paulo, Brazil
hcfmusp.description.beginpage200
hcfmusp.description.endpage204
hcfmusp.description.issue3
hcfmusp.description.volume36
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000509791000001
hcfmusp.origem.id2-s2.0-85081945783
hcfmusp.publisher.cityNEW ROCHELLEeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAmaral AG, 2017, MEM I OSWALDO CRUZ, V112, P411, DOI 10.1590/0074-02760160458eng
hcfmusp.relation.referenceAndreatta K, 2015, JAIDS-J ACQ IMM DEF, V68, P519, DOI 10.1097/QAI.0000000000000503eng
hcfmusp.relation.reference[Anonymous], 2019, HIV DRUG RES REP 201eng
hcfmusp.relation.referenceBarreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338eng
hcfmusp.relation.referenceBbosa N, 2019, CURR OPIN HIV AIDS, V14, P153, DOI 10.1097/COH.0000000000000534eng
hcfmusp.relation.referenceBennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724eng
hcfmusp.relation.referenceBoyd MA, 2015, LANCET HIV, V2, pE42, DOI 10.1016/S2352-3018(14)00061-7eng
hcfmusp.relation.referenceClutter DS, 2016, JAIDS-J ACQ IMM DEF, V72, P171, DOI 10.1097/QAI.0000000000000942eng
hcfmusp.relation.referenceGuimaraes PMD, 2015, AIDS RES HUM RETROV, V31, P1219, DOI [10.1089/aid.2014.0354, 10.1089/AID.2014.0354]eng
hcfmusp.relation.referenceDuani H, 2017, BRAZ J INFECT DIS, V21, P148, DOI 10.1016/j.bjid.2016.11.009eng
hcfmusp.relation.referenceFerreira ACG, 2017, BRAZ J INFECT DIS, V21, P396, DOI 10.1016/j.bjid.2017.03.013eng
hcfmusp.relation.referenceGodfrey C, 2017, J INFECT DIS, V216, pS798, DOI 10.1093/infdis/jix137eng
hcfmusp.relation.referenceGonsalez CR, 2007, VIRUS RES, V129, P87, DOI 10.1016/j.virusres.2007.06.021eng
hcfmusp.relation.referenceGregson J, 2016, LANCET INFECT DIS, V16, P565, DOI 10.1016/S1473-3099(15)00536-8eng
hcfmusp.relation.referenceGupta RK, 2013, J INFECT DIS, V207, pS101, DOI 10.1093/infdis/jit108eng
hcfmusp.relation.referenceHan XX, 2007, AIDS RES HUM RETROV, V23, P357, DOI 10.1089/aid.2006.0094eng
hcfmusp.relation.referenceLuo XL, 2019, J PHARMACOL SCI, V139, P275, DOI 10.1016/j.jphs.2018.11.016eng
hcfmusp.relation.referenceMargot NA, 2017, J INFECT DIS, V215, P920, DOI 10.1093/infdis/jix015eng
hcfmusp.relation.referenceMatsuda EM, 2018, AIDS RES HUM RETROV, V34, P156, DOI [10.1089/aid.2017.0052, 10.1089/AID.2017.0052]eng
hcfmusp.relation.referenceMinisterio da Saude, 2018, PROT CLIN DIR TER MAeng
hcfmusp.relation.referenceMinisterio da Saude-Secretaria de Vigilancia em Saude-Departamento de DST AeHV, 2015, B EP AIDS DST 2015eng
hcfmusp.relation.referenceCoelho LPO, 2019, ARCH VIROL, V164, P699, DOI 10.1007/s00705-018-04122-8eng
hcfmusp.relation.referencePanichsillapakit T, 2016, JAIDS-J ACQ IMM DEF, V71, P228, DOI 10.1097/QAI.0000000000000831eng
hcfmusp.relation.referenceRiemenschneider M, 2016, CURR HIV RES, V14, P307, DOI 10.2174/1570162X14666160321120232eng
hcfmusp.relation.referenceWeber IT, 2015, FUTURE MED CHEM, V7, P2301, DOI 10.4155/fmc.15.149eng
hcfmusp.relation.referenceWHO, 2017, HIV DRUG RES REP 201eng
hcfmusp.relation.referenceWittkop L, 2011, LANCET INFECT DIS, V11, P363, DOI 10.1016/S1473-3099(11)70032-9eng
hcfmusp.relation.referenceWorld Health Organization (WHO), 2017, GLOB ACT PLAN HIV DReng
hcfmusp.relation.referenceZu Knyphausen F, 2014, PLOS ONE, pe95956eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1931-8405
hcfmusp.citation.scopus0-
hcfmusp.scopus.lastupdate2022-09-23-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDT
Departamento de Dermatologia - FM/MDT

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - IMT
Instituto de Medicina Tropical - IMT

Artigos e Materiais de Revistas Científicas - LIM/38
LIM/38 - Laboratório de Epidemiologia e Imunobiologia

Artigos e Materiais de Revistas Científicas - LIM/48
LIM/48 - Laboratório de Imunologia

Artigos e Materiais de Revistas Científicas - LIM/56
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Artigos e Materiais de Revistas Científicas - ODS/05
ODS/05 - Igualdade de gênero


Files in This Item:
File Description SizeFormat 
art_CONSTANTINOV_Prevalence_of_Antiretroviral_Drug_Resistance_Mutations_in_HIV_2020.PDF
  Restricted Access
publishedVersion (English)101.11 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.